Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Consortium Pioneers New AMR Development Model

Executive Summary

A new consortium that has won funding from the French government will focus on developing new treatments, diagnostics and surveillance and make sure that these approaches are properly valued by involving health economists in new drug development.

You may also be interested in...



Support For Small Companies In AMR Space Is Crucial Now

G7 countries should look to US PASTEUR Act For Inspiration On Pull Incentives for Antimicrobials

US PASTEUR Act Promises More Than Other National AMR Initiatives

PASTEUR Act in the US is the most promising initiative out there to address antimicrobial resistance.

Added Benefit For Orphans Is ‘Fictitious’ Says German HTA Body

Industry has warned that reforming the system for evaluating orphan drugs could have serious consequences for patient access.

Topics

UsernamePublicRestriction

Register

PS145476

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel